Metastatic breast cancer trials in Spain

In Spain 74 Also abroad 610

74 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Where
Barcelona, Madrid, Pamplona, Pozuelo de Alarcón
Age
18 years and over
People
380 worldwide
Run by
BioNTech SE
See details and how to joinNCT06827236 · EU 2024-517979-20-00
Phase 1Taking people
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Where
Logrono, Madrid, Valencia
Age
18 years and over
People
150 worldwide
Run by
IDEAYA Biosciences
See details and how to joinNCT07503808 · EU 2026-526299-21-00
Phase 2Taking people
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Where
Barcelona, Bilbao, Lleida, Madrid, Málaga, Seville
Age
18 years and over
People
120 worldwide
Run by
ALX Oncology Inc.
See details and how to joinNCT07007559
Phase 3Taking people
BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer
Where
Badajoz, Barcelona, Donostia, Elche, Granada, Madrid, Santiago de Compostela, Sevilla
Age
18 years and over
People
233 worldwide
Run by
BeOne Medicines I GmbH
See details and how to joinNCT07492641 · EU 2025-523960-19-00
Phase 1/2Taking people
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Where
Barcelona, Madrid, Sevilla
Age
18 years and over
People
1,132 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00
Phase 1/2Taking people
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Where
A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Seville, Valencia
Age
18 years and over
People
910 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06324357
Phase 3Taking people
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Where
Badajoz, Badalona, Barcelona, Cáceres, Castello De La Plana, Girona, Huelva, Jaén, L'Hospitalet de Llobregat, Lleida, Madrid, Murcia, Palma, Pamplona, San Cristóbal de La Laguna, Sant Cugat del Vallès, Sevilla, Valencia
Age
18 years and over
People
540 worldwide
Run by
Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00
Phase 1Taking people
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Where
Barcelona, Madrid, Valencia
Age
18 years and over
People
260 worldwide
Run by
Pfizer
See details and how to joinNCT07318805 · EU 2025-524387-38-00
Phase 2/3Taking people
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Where
Barcelona, Bilbao, EL Palmar (EL Palmar), Granada, Jaén, Madrid, Málaga, San Cristóbal de La Laguna, Seville, Valencia
Age
18 years and over
People
650 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Where
Barcelona, Bilbao, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Sevilla, Valencia
Age
18 years and over
People
450 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00
Phase 3Taking people
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Where
Badajoz, Barcelona, Cáceres, Donostia / San Sebastian, Granada, Hospitalet, Jaén, Las Palmas de Gran Canaria, Lleida, Madrid, Málaga, Palma, Salamanca, San Cristóbal de La Laguna, Santiago de Compostela, Seville, Valencia, Zaragoza
Age
18 years and over
People
800 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00
Phase 3Taking people
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Where
A Coruña, Badalona, Barcelona, Madrid, Santander, Seville
Age
18 years and over
People
1,000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00
Phase 2Taking people
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Where
Barcelona, Granada, Madrid, Valencia
Age
18 years and over
People
80 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07368998 · EU 2025-522805-39-00
Phase 2Taking people
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Where
Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Valencia
Age
18 years and over
People
80 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07405801 · EU 2025-523013-28-00
Phase 1Taking people
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
Where
Madrid
Age
18 years and over
People
194 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07604571
Phase 1/2Taking people
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
Where
Barcelona, Madrid, Pamplona
Age
18 years and over
People
20
Run by
Fundacio Clinic Barcelona
See details and how to joinNCT05451784 · EU 2024-511915-21-01
Phase 3Taking people
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
Where
A Coruña, Alicante, Badajoz, Badalona, Barcelona, Elche, Granada, Lleida, Madrid, Palma, San Cristóbal de La Laguna, Santiago de Compostela, Sevilla, Valencia, Vigo
Age
18 years and over
People
264 worldwide
Run by
Jazz Pharmaceuticals Ireland Limited
See details and how to joinNCT06435429 · EU 2023-508960-31-00
Phase 3Taking people
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Where
Barcelona, Cáceres, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Sevilla, Valencia
Age
18 years and over
People
788 worldwide
Run by
AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00
Phase 3Taking people
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Where
Barcelona, Córdoba, Madrid, Málaga, Pamplona, Valencia
Age
18 years and over
People
600 worldwide
Run by
LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Where
Barcelona, Cáceres, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, San Cristobal De La Laguna, Santiago de Compostela, Sevilla
Age
18 years and over
People
420 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Sevilla
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1Not yet taking people in Spain
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Barcelona, L'Hospitalet de Llobregat, Madrid
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00
Phase 1Taking people
A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
Where
Madrid, Valencia
Age
18 years and over
People
40 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-522707-26-00 · EU 2025-522707-26-00
Phase 1/2Not yet taking people in Spain
A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer
Where
Barcelona, Madrid, Pamplona
Age
18 years to 64 years
People
18
Run by
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
See details and how to join2026-527365-30-00 · EU 2026-527365-30-00
Phase 2Taking people
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Where
L'Hospitalet de Llobregat, Madrid
Age
18 years and over
People
90 worldwide
Run by
Delcath Systems Inc.
See details and how to joinNCT06875128 · EU 2025-521966-91-00